News Lilly/Boehringer diabetes combos get cardio data boost Lilly/Boehringer gain further advantage in US diabetes market.
News Juno halts CAR-T trial again after 2 more deaths Doubts over Juno CAR-T therapy after two more trial deaths.
News Alnylam plunges after deaths in rare disease trial Biotech axes revusiran due to safety concerns.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
